The University of lowa/Mayo Clinic (UI/MC) Lymphoma SPORE is a dynamic, productive, translational cancer research program based at two comprehensive cancer centers that was first funded in 2002 and competitively renewed in 2007. At the center of the ongoing success of the UI/MC SPORE is the collaborative interaction between investigators at lowa and Mayo, as well as SPORE basic laboratory, clinical and population-based investigators. The overall goal of the SPORE is to support innovative, interactive, translational research into lymphoma and chronic lymphocytic leukemia that leverages the expertise of laboratory, clinical and population-based research at both institutions. Over the last funding period, the SPORE has been highly productive as demonstrated by identification of new tumor markers, scientific findings that led to additional translational lymphoma grants from the NCI, multiple publications including many authored by investigators from both institutions, and brisk accrual to translational clinical trials. The UI/MC Molecular Epidemiology Resource is based in the SPORE, and serves as a vital resource for both SPORE research and research projects supported by other grants. The current proposal will build on past successes and support 4 major research projects that represent new concepts that emerged from research supported over the past funding period. Support will also be provided to pursue novel translational concepts in lymphoma research and new investigators through the Developmental Research and Career Development programs. Finally, the SPORE will enhance the infrastructure that supports translational lymphoma research at both institutions through shared core resources in Administration, Biostatistics and Bioinformatics, Biospecimens and Clinical Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-13
Application #
8689944
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Nothwehr, Steven F
Project Start
2002-09-11
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Iowa City
State
IA
Country
United States
Zip Code
52242
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Ravi, Praful; Kumar, Shaji K; Cerhan, James R et al. (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598
Pophali, Priyanka A; Ip, Andrew; Larson, Melissa C et al. (2018) The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol 93:1543-1550
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Maurer, M J; Habermann, T M; Shi, Q et al. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29:1822-1827
Shenoy, Niraj; Creagan, Edward; Witzig, Thomas et al. (2018) Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell 34:700-706

Showing the most recent 10 out of 387 publications